Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By | May 18th, 2017|Chronix news|0 Comments

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 15th, 2017|Peer-reviewed medical publications|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

By | May 14th, 2017|Peer-reviewed medical publications|0 Comments

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | May 13th, 2017|Peer-reviewed medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | May 12th, 2017|Peer-reviewed medical publications|0 Comments

Rectal Cancer Treatment Outcome Predictions

Beck, J. et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy. J ClinOncol 32, 2014 (suppl; abstr e14549).

Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH [2014] The Cancer Genome Atlas).

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | May 9th, 2017|Peer-reviewed medical publications|0 Comments

Digital PCR of cfDNA for Transplant Rejetion

Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41

Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.

By | May 7th, 2017|Peer-reviewed medical publications|0 Comments

NGS of prostate cancer

Schütz, E. et al. Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. J ClinOncol 28:15s, 2010 (suppl; abstr 10505).

The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.

By | May 6th, 2017|Peer-reviewed medical publications|0 Comments

NGS of cell-free DNA in animals

Gordon, Paul MK, et al. Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with transmissible spongiform encephalopathies. Nucleic Acids Research 37.2 (2009): 550-556.

In a 25-month time-course experiment, CNAs were isolated from blood samples of 24 elk (Cervuselaphus) orally challenged with chronic wasting disease (CWD) infectious material.Our results may become useful for the early diagnosis of TSE in live elk and cattle.

By | May 4th, 2017|Peer-reviewed medical publications|0 Comments